A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies

Rheumatology (United Kingdom)

Volumn 56, Issue 6, 2017, Pages 999-1007

  Pinal Fernandez, Iago ^a   Casal Dominguez, Maria ^b   Huapaya, Julio A ^b   Albayda, Jemima ^b   Paik, Julie J ^b   Johnson, Cheilonda ^b   Silhan, Leann ^b   Christopher Stine, Lisa ^b   Mammen, Andrew L ^a   Danoff, Sonye K ^b  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti Ro52; Anti synthetase antibodies; Anti synthetase syndrome; Cohort study; Dermatomyositis; Myositis; Polymyositis; Prognostic factors

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CREATINE KINASE; CYCLOSPORIN; IMMUNOGLOBULIN; JO 1 ANTIBODY; METHOTREXATE; MYCOPHENOLATE MOFETIL; PL12 ANTIBODY; PL7 ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ANTISYNTHETASE SYNDROME; ARTICLE; BLACK PERSON; CANCER INCIDENCE; CANCER RISK; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PREVALENCE; PRIORITY JOURNAL; AFRICAN AMERICAN; DISEASE COURSE; ETHNOLOGY; IMMUNOLOGY; METABOLISM; MUSCLE DISEASE; MYOSITIS;

AFRICAN AMERICANS; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUSCULAR DISEASES; MYOSITIS;

EID: 85021125272     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex021     Document Type: Article

References (26)

1. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980;23:881-8.
2. Mathews MB, Reichlin M, Hughes GR, Bernstein RM. Antithreonyl- tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984;160:420-34.
3. Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med 1986;163:1281-91.
4. TargoffIN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990;144:1737-43.
5. Hirakata M, Suwa A, Nagai S et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999;162:2315-20.
6. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 2007;46:1005-8.
7. Hashish L, Trieu EP, Sadanandan P, TargoffIN. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome. Arthritis Rheum 2005;52:S312.
8. Hervier B, Devilliers H, Stanciu R et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012;12:210-7.
9. Marie I, Josse S, Decaux O et al. Comparison of long-term outcome between anti-Jo1-and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012;11:739-45.
10. Kalluri M, Sahn SA, Oddis CV et al. Clinical profile of anti- PL-12 autoantibody. Cohort study and review of the literature. Chest 2009;135:1550-6.
11. Marie I, Hatron PY, Dominique S et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti- Ro52 antibody. Semin Arthritis Rheum 2012;41:890-9.
12. Aggarwal R, Cassidy E, Fertig N et al. Patients with non- Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014;73:227-32.
13. Trallero-Araguás E, Grau-Junyent JM, Labirua-Iturburu A et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum 2016;46:225-31.
14. Cavagna L, Nuño L, ScirèCA et al. Clinical spectrum time course in Anti Jo-1 positive antisynthetase syndrome: results from an International Retrospective Multicenter Study. Medicine 2015;94:e1144.
15. Rider LG, Werth VP, Huber AM et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 2011;63 (Suppl 11):S118-57.
16. Travis WD, Costabel U, Hansell DM et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
17. MacIntyre N, Crapo RO, Viegi G et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720-35.
18. Troyanov Y, TargoffIN, Tremblay JL et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005;84:231-49.
19. Werner JL, Christopher-Stine L, Ghazarian SR et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012;64:4087-93.
20. Pinal-Fernandez I, Parks C, Werner JL et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res 2017;69:263-70.
21. Mulcahy KP, Langdon PC, Mastaglia F. Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence. Dysphagia 2012;27:64-9.
22. Oh TH, Brumfield KA, Hoskin TL et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 2007;82:441-7.
23. Johnson C, Pinal-Fernandez I, Parikh R et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 2016;194:733-7.
24. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66:1345-9.
25. Rutjes SA, Vree Egberts WT, Jongen P et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.
26. Johnson C, Connors GR, Oaks J et al. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med 2014;108:1542-8.